https://www.selleckchem.com/pr....oducts/Mubritinib-TA
7 years for the RFA group, and 3.8 years for the SBRT group. The proportion of the patients with CCI ≧3 was significantly higher in the group of RFA/SBRT than surgery ( 0.0001). In selected patients with CCI ≧3, there was no difference of the median survival time between the surgery group and the RFA group. We could have other treatment options to provide nonsurgical local therapies (RFA/SBRT) for elderly, vulnerable CRLM patients who have risks for surgery. We could have other treatment options to provide nonsurgical l
Like
Comment
Share
